CSPAM
ACAD icon

Cary Street Partners Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Cary Street Partners Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-16,840
Closed -$17K – 155
2021
Q1 		$17K Sell
16,840
-11,695
-41% -$515K ﹤0.01% 177
2020
Q4 		$642K Buy
+28,535
New +$1.42M 0.19% 106

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Cary Street Partners Asset Management's ACAD Position: Q2 2021 in Review

Cary Street Partners Asset Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2021, closing a stake of 16,840 shares — an estimated $17K sold.

Cary Street Partners Asset Management first reported a position in ACAD in Q4 2020 and held it in 2 quarters. The position peaked at $642K in Q4 2020. 244 funds tracked by Wall St. Rank hold ACAD as of Q2 2021.

  • Cary Street Partners Asset Management reported no remaining Acadia Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Cary Street Partners Asset Management sold 16,840 Acadia Pharmaceuticals shares in Q2 2021, an estimated $17K.
  • Cary Street Partners Asset Management first reported a position in Acadia Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • Cary Street Partners Asset Management's Acadia Pharmaceuticals position peaked at $642K in Q4 2020.
  • 244 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2021.

Based on Cary Street Partners Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.